US2016032260A1PendingUtilityA1
T7 rna polymerase variants with enhanced thermostability
Assignee: ROCHE DIAGNOSTICS OPERATIONSPriority: Apr 16, 2010Filed: Oct 16, 2015Published: Feb 4, 2016
Est. expiryApr 16, 2030(~3.7 yrs left)· nominal 20-yr term from priority
Inventors:Harald SobekJohann-Peter ThalhoferRainer MuellerManfred SchmidtMichael GreifArmin RufChristian Rudolph
C12P 19/34C12N 9/1247C12Y 207/07006
55
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention provides improved variants of T7 RNA polymerase by introducing novel mutations which lead to improved thermostability of the enzyme. According to the invention, amino acid substitutions at the positions Val426, Ser633, Val650, Thr654, Ala702, Val795, and combinations thereof are advantageous.
Claims
exact text as granted — not AI-modified1 - 15 . (canceled)
16 . A method for producing a variant polypeptide of T7 RNA polymerase (T7 variant), the T7 variant having (i) a DNA-dependent RNA polymerase activity, (ii) an enhanced thermostability compared to SEQ ID NO: 2 (wild-type reference), and (iii) a different composition of amino acids compared to the wild-type reference, the method comprising the steps of:
(a) selecting an amino acid from the group consisting of Val426, Ser633, Val650, Thr654, Ala702, and Val795, numbered from the N-terminus of the wild-type reference; (b) substituting the selected amino acid with a different amino acid to form a T7 variant, wherein the different amino acid is selected from the group consisting of:
Leu, and Ile when the different amino acid substitutes for Val426 (Val426Leu, Val426Ile),
Val and Met when the different amino acid substitutes for Ser633 (Ser633Val, Ser633Met),
Leu when the different amino acid substitutes for Val650 (Val650Leu),
Leu when the different amino acid substitutes for Thr654 (Thr654Leu),
Val when the different amino acid substitutes for Ala702 (Ala702Val), and
Ile when the different amino acid substitutes for Val795 (Val795Ile),
wherein at least one amino acid of the wild-type reference and up to four amino acids at different positions are substituted; and (c) expressing a nucleic acid molecule with a nucleotide sequence encoding the T7 variant of step (b) in an expression system, and isolating the expressed T7 variant from the expression system, thereby producing the T7 variant.
17 . A method for producing a nucleic acid molecule with a nucleotide sequence encoding a variant polypeptide of T7 RNA polymerase (T7 variant), the T7 variant having (i) a DNA-dependent RNA polymerase activity, (ii) an enhanced thermostability compared to SEQ ID NO: 2 (wild-type reference), and (iii) a different composition of amino acids compared to the wild-type reference, the method comprising the steps of:
synthesizing at least one nucleic acid molecule encoding at least one variant polypeptide of T7 RNA polymerase; wherein the T7 variant comprises a polypeptide of the wild-type reference in which at least one amino acid and up to four amino acids at different positions are substituted, wherein a different amino acid substitutes for an amino acid selected from the group consisting of Val426, Ser633, Val650, Thr654, Ala702, and Val795, numbered from the N-terminus of the wild-type reference, and wherein the different amino acid is selected from the group consisting of
Leu, Ile and Phe when the different amino acid substitutes for Val426 (Val426Leu, Val426Ile, Val426Phe),
Val and Met when the different amino acid substitutes for Ser633 (Ser633Val, Ser633Met),
Leu when the different amino acid substitutes for Val650 (Val650Leu),
Leu when the different amino acid substitutes for Thr654 (Thr654Leu),
Val when the different amino acid substitutes for Ala702 (Ala702Val), and
Ile when the different amino acid substitutes for Val795 (Val795Ile).
18 . A nucleic acid molecule with a nucleotide sequence encoding a variant polypeptide of T7 RNA polymerase (T7 variant), the T7 variant having (i) a DNA-dependent RNA polymerase activity, (ii) an enhanced thermostability compared to SEQ ID NO: 2 (wild-type reference), and (iii) a different composition of amino acids compared to the wild-type reference, the nucleic acid being obtainable by the method of claim 17 .
19 . The nucleic acid molecule according to claim 18 , wherein the nucleotide sequence of the nucleic acid comprises a sequence selected from the group consisting of SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 29, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 41, SEQ ID NO: 43, and SEQ ID NO: 47.
20 . The nucleic acid molecule according to claim 18 , wherein the nucleic acid molecule is functionally linked to one or more nucleotide sequences capable of controlling transcription and/or translation to form an expression vector.
21 . The nucleic acid molecule according to claim 20 , wherein the expression vector transforms a host organism.Join the waitlist — get patent alerts
Track US2016032260A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.